API-gated journals may skew pharma regulatory research as AI agents favor accessible sources, raising citation integrity and pharmacovigilance risks.
|Articles|September 2, 2009
- Pharmaceutical Technology-09-02-2009
- Volume 33
- Issue 9
Pharmaceutical Technology, September 2009 Issue (PDF)
Robots Lend a Hand
Advertisement
Articles in this issue
about 17 years ago
Pharma Capsulesabout 17 years ago
Of Audits and Gunkabout 17 years ago
Quality by Enforcementabout 17 years ago
Robots: The Next Phase in Pharmaceutical Automationabout 17 years ago
It's Easy Being Greenabout 17 years ago
Expansion Planabout 17 years ago
A Green Manufacturing Route to Testosteroneabout 17 years ago
In the Spotlight September 2009about 17 years ago
Pill-Level Product ProtectionAdvertisement
Related to this article
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Winners of the 2026 CPHI Pharma Awards Announced
2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
3
Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
4
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
5